Management of hepatocellular carcinoma
- 1.4k Downloads
Hepatocellular carcinoma (HCC), a common cause for cancer-related death, is increasing worldwide. Over the past decade, survival and quality of life of HCC patients have significantly improved due to better prevention strategies, early diagnosis, and improved treatment options. We performed this narrative review to synthesize current status on the HCC management.
Literature search for publications especially over the last decade, which has changed the paradigm on the management of HCC.
Hepatitis B vaccination and treatment of chronic hepatitis B and C are important measures for HCC prevention. Screening and surveillance for HCC using ultrasonogram and alpha-fetoprotein estimation are directed toward cirrhotics and hepatitis B patients at high risk of HCC. If detected at an early stage, curative treatments for HCC can be used such as tumor resection, ablation and liver transplantation. HCC patients without curative options are managed by loco-regional therapies and systemic chemotherapy. Loco-regional treatments include trans-arterial chemoembolization, radioembolization and combinations of loco-regional plus systemic therapies. Currently, sorafenib is the only FDA-approved systemic therapy and newer better chemotherapeutic agents are being investigated. Palliative care for terminally ill patients with metastatic disease and/or poor functional status focusses on comfort care and symptom control.
In spite of significant advancement in HCC management, its incidence continues to rise. There remains an urgent need to continue refining understanding of HCC and develop strategies to increase utilization of the available preventive measures and curative treatment modalities for HCC.
KeywordsPrevention Transplantation Loco-regional therapy Systemic therapy
Conflict of interest
We declare that we have no conflict of interests.
- Bruix J, Tak WY, Gasbarrini A, Santoro A, Colombo M, Lim HY, Mazzaferro V, Wiest R, Reig M, Wagner A, Bolondi L (2013) Regorafenib as second-line therapy for intermediate or advanced hepatocellular carcinoma: multicentre, open-label, phase II safety study. Eur J Cancer 49(16):3412–3419PubMedCrossRefGoogle Scholar
- Cescon M, Cucchetti A, Grazi GL, Ferrero A, Vigano L, Ercolani G et al (2009) Indication of the extent of hepatectomy for hepatocellular carcinoma on cirrhosis by a simple algorithm based on preoperative variables. Arch Surg 144(1):57–63; discussion 63Google Scholar
- Cholongitas E, Mamou C, Rodriguez-Castro KI, Burra P (2014) Mammalian target of rapamycin inhibitors are associated with lower rates of hepatocellular carcinoma recurrence after liver transplantation: a systematic review. Transpl Int. doi: 10.1111/tri.12372
- Delis SG, Bakoyiannis A, Biliatis I, Athanassiou K, Tassopoulos N, Dervenis C (2009) Model for end-stage liver disease (MELD) score, as a prognostic factor for post-operative morbidity and mortality in cirrhotic patients, undergoing hepatectomy for hepatocellular carcinoma. HPB (Oxford) 11(4):351–357CrossRefGoogle Scholar
- Diouf M, Filleron T, Barbare JC, Fin L, Picard C, Bouché O, Dahan L, Paoletti X, Bonnetain F (2013) The added value of quality of life (QoL) for prognosis of overall survival in patients with palliative hepatocellular carcinoma. J Hepatol 2013(58):3Google Scholar
- El-Serag HB (2001) Epidemiology of hepatocellular carcinoma. Clin Liver Dis 5(1):87–107, viGoogle Scholar
- Evan RJ, Kakati D, Shoreibah MG, Bloomer JR, Singal AK (2014) CT scans are overused for hepatocellular carcinoma screening in patients with cirrhosis. Gastroenterology 146(Suppl.), AbstractGoogle Scholar
- Jepsen P, Ott P, Andersen PK, Sorensen HT, Vilstrup H (2012) Risk for hepatocellular carcinoma in patients with alcoholic cirrhosis: a Danish nationwide cohort study. Ann Intern Med 156(12):841–847, W295Google Scholar
- Johnson PJ, Qin S, Park JW, Poon RT, Raoul JL, Philip PA, Hsu CH, Hu TH, Heo J, Xu J, Lu L, Chao Y, Boucher E, Han KH, Paik SW, Robles-Aviña J, Kudo M, Yan L, Sobhonslidsuk A, Komov D, Decaens T, Tak WY, Jeng LB, Liu D, Ezzeddine R, Walters I, Cheng AL (2013) Brivanib versus sorafenib as first line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized phase III BRISK-FL study. J Clin Oncol 31(28):3517–3524PubMedCrossRefGoogle Scholar
- Kudo M, Han G, Finn RS, Poon RT, Blanc JF, Yan L, Yang J, Lu L, Tak WY, Yu X, Lee JH, Lin SM, Wu C, Tanwandee T, Shao G, Walters IB, Dela Cruz C, Poulart V, Wang JH (2014) Brivanib as adjuvant therapy to transarterial chemoembolization in patients with hepatocellular carcinoma: a randomized phase 3 trial. Hepatology. doi: 10.1002/hep.27290
- Lammer J, Malagari K, Vogl T, Pilleul F, Denys A, Watkinson A et al (2010) Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. Cardiovasc Intervent Radiol 33(1):41–52PubMedCentralPubMedCrossRefGoogle Scholar
- Livraghi T, Meloni F, Di Stasi M, Rolle E, Solbiati L, Tinelli C et al (2008) Sustained complete response and complications rates after radiofrequency ablation of very early hepatocellular carcinoma in cirrhosis: is resection still the treatment of choice? Hepatology 47(1):82–89PubMedCrossRefGoogle Scholar
- Llovet JM, Decaens T, Raoul JL, Boucher E, Kudo M, Chang C, Kang YK, Assenat E, Lim HY, Boige V, Mathurin P, Fartoux L, Lin DY, Bruix J, Poon RT, Sherman M, Blanc JF, Finn RS, Tak WY, Chao Y, Ezzeddine R, Liu D, Walters I, Park JW (2013) Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS study. J Clin Oncol 31(28):3509–3516PubMedCrossRefGoogle Scholar
- Maithel SK, Kneuertz PJ, Kooby DA, Scoggins CR, Weber SM, Martin RC, 2nd et al (2011) Importance of low preoperative platelet count in selecting patients for resection of hepatocellular carcinoma: a multi-institutional analysis. J Am Coll Surg 212(4), 638–648; discussion 648–650Google Scholar
- Majno PE, Adam R, Bismuth H, Castaing D, Ariche A, Krissat J et al (1997) Influence of preoperative transarterial lipiodol chemoembolization on resection and transplantation for hepatocellular carcinoma in patients with cirrhosis. Ann Surg 226(6):688–701; discussion 701–683Google Scholar
- Malagari K, Chatzimichael K, Alexopoulou E, Kelekis A, Hall B, Dourakis S et al (2008) Transarterial chemoembolization of unresectable hepatocellular carcinoma with drug eluting beads: results of an open-label study of 62 patients. Cardiovasc Intervent Radiol 31(2):269–280PubMedCrossRefGoogle Scholar
- Mazzaferro V, Sposito C, Bhoori S, Romito R, Chiesa C, Morosi C, Maccauro M, Marchianò A, Bongini M, Lanocita R, Civelli E, Bombardieri E, Camerini T, Spreafico C (2013) Ytrium-90 radioembolization for intermediate-advanced hepatocellular carcinoma: a phase 2 study. Hepatology 57(5):1826–1837PubMedCrossRefGoogle Scholar
- Morimoto O, Nagano H, Sakon M, Fujiwara Y, Yamada T, Nakagawa H et al (2003) Diagnosis of intrahepatic metastasis and multicentric carcinogenesis by microsatellite loss of heterozygosity in patients with multiple and recurrent hepatocellular carcinomas. J Hepatol 39(2):215–221PubMedCrossRefGoogle Scholar
- National Comprehensive Cancer Network Guidelines. www.nccn.org
- Nicolini D, Svegliati-Baroni G, Candelari R, Mincarelli C, Mandolesi A, Bearzi I et al (2013) Doxorubicin-eluting bead vs conventional transcatheter arterial chemoembolization for hepatocellular carcinoma before liver transplantation. World J Gastroenterol 19(34):5622–5632PubMedCentralPubMedCrossRefGoogle Scholar
- Salem R, Lewandowski RJ, Mulcahy MF, Riaz A, Ryu RK, Ibrahim S, Atassi B, Baker T, Gates V, Miller FH, Sato KT, Wang E, Gupta R, Benson AB, Newman SB, Omary RA, Abecassis M, Kulik L (2010) Radioembolization for hepatocellular carcinoma using Ytrium-90 microspheres: a comprehensive report of long-term outcomes. J Gastroenterol 138(1):52–64CrossRefGoogle Scholar
- Salem R, Lewandowski RJ, Kulik L, Wang E, Riaz A, Ryu RK et al (2011) Radioembolization results in longer time-to-progression and reduced toxicity compared with chemoembolization in patients with hepatocellular carcinoma. Gastroenterology 140(2):497–507 e492Google Scholar
- Salem R, Gilbertsen M, Butt Z, Memon K, Vouche M, Hickey R, Baker T, Abecassis MM, Atassi R, Riaz A, Cella D, Burns JL, Ganger D, Benson AB 3rd, Mulcahy MF, Kulik L, Lewandowski R (2013) Increased quality of life among hepatocellular carcinoma patients treated with radioembolization, compared with chemoembolization. Clin Gastroenterol Hepatol 11(10):1358–1365PubMedCrossRefGoogle Scholar
- Singal AK, Fontana RJ (2011) Oral antiviral agents reduce the risk of hepatocellular carcinoma in patients with chronic hepatitis B: systematic review and meta-analysis. Hepatology 54:1016AGoogle Scholar
- Teh SH, Christein J, Donohue J, Que F, Kendrick M, Farnell M et al (2005) Hepatic resection of hepatocellular carcinoma in patients with cirrhosis: Model of End-Stage Liver Disease (MELD) score predicts perioperative mortality. J Gastrointest Surg 9(9):1207–1215; discussion 1215Google Scholar
- Ulahannan SV, Duffy AG, McNeel TS, Kish JK, Dickie LA, Rahma OE et al (2014) Earlier presentation and application of curative treatments in hepatocellular carcinoma. Hepatology. doi: 10.1002/hep.27288
- Welch J, Shukla R, Igbo NL, Singal AK, Kazan-Tannus JF, Soloway RD (2010) Use of ultrasound as initial imaging exam for hepatocellular carcinoma in high risk populations. Gastroenterology (Suppl.):S219Google Scholar
- Zhang L, Hu P, Chen X, Bie P (2014) Transarterial chemoembolization (TACE) plus sorafenib versus TACE for intermediate or advanced stage hepatocellular carcinoma: a meta-analysis. PLoS One 9(6):e100305Google Scholar